Related Experiment Video

Updated: Aug 9, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Potential of DMXAA combination therapy for solid tumors

Bruce C Baguley1, William R Wilson

  • 1Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand. b.baguley@auckland.ac.nz

Expert Review of Anticancer Therapy
|October 18, 2002
PubMed

Insights

DMXAA, a novel anticancer agent, targets tumor blood vessels to reduce blood supply. It works by inducing cytokines like tumor necrosis factor and shows synergistic effects with radiation and chemotherapy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Immunology

Background:

  • DMXAA represents a new class of anticancer agents targeting tumor vasculature.
  • Tumor blood vessel disruption deprives tumor tissue of essential blood supply.
  • DMXAA's mechanism involves inducing cytokines, notably tumor necrosis factor.

Purpose of the Study:

  • To review the mechanisms of DMXAA's action.
  • To explore DMXAA's interactions with radiation, hyperthermia, and chemotherapy.
  • To discuss the clinical exploitation of these interactions in cancer treatment.

Main Methods:

  • Review of existing literature on DMXAA.
  • Analysis of DMXAA's molecular mechanisms.
  • Examination of preclinical data on combination therapies.

Main Results:

  • DMXAA effectively disrupts tumor vasculature.
  • DMXAA induces pro-inflammatory cytokine production in tumors.
  • Synergistic interactions observed between DMXAA and other cancer treatments.

Conclusions:

  • DMXAA is a promising anticancer agent with a unique vascular-targeting mechanism.
  • Combination strategies involving DMXAA may enhance therapeutic outcomes.
  • Further clinical investigation is warranted to exploit DMXAA's potential in cancer therapy.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...